Anwendung von Omalizumab-Biosimilars bei CRSwNP im deutschen Gesundheitssystem – ein Positionspapier von AeDA und DGHNO-KHC
Laryngo-Rhino-Otologie · 01.04.2026 · 105 (04) · 210-223
DOI: 10.1055/a-2797-4119 ↗Kurz gefasst
Leitlinie in der Zeitschrift Laryngo-Rhino-Otologie, erschienen am 01.04.2026. Verfasst von L Klimek und 30 weiteren Autor:innen. Beteiligte Einrichtung: Zentrum für Rhinologie und Allergologie, Wiesbaden. Hauptthemen laut MEDLINE: Omalizumab, Rhinosinusitis, Nasal Polyps, Biosimilar Pharmaceuticals.
Abstract (Originalsprache)
Background
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a multifactorial inflammatory disease of the nasal and paranasal mucosa, most often caused by TH2 inflammation. IgE antibodies play an important role in this disease. The anti-IgE antibody omalizumab was approved in August 2020 for the treatment of patients aged 18 years and older with severe CRSwNP as add-on therapy to intranasal corticosteroids (INCS) when adequate disease control cannot be achieved with INCS alone. Omlyclo, a biosimilar of Xolair containing the active ingredient omalizumab (CT-P39), was approved in the EU in May 2024. In Germany, Omlyclo has been officially available by prescription since September 15, 2025, and is available as 75 mg and 150 mg pre-filled syringes and pre-filled pens. An extension of the marketing authorization for the 300 mg dosage followed in November 2025.
Methods
A literature search was conducted to analyze the immunology of CRSwNP and to identify the evidence for the efficacy of omalizumab in this disease through searches in Medline, PubMed, national and international study and guideline registries, and the Cochrane Library.
Results
Based on this information from the international literature, an expert panel from the Association of German Allergists and the German Society for Otorhinolaryngology and Head and Neck Surgery provides recommendations for the use of the omalizumab biosimilar CTP39 in CRSwNP within the German healthcare system.
Conclusion
The omalizumab biosimilar is approved for patients aged 18 years and older with severe chronic rhinosinusitis with nasal polyps as add-on therapy to intranasal corticosteroids when adequate disease control cannot be achieved with singel intranasal corticosteroids therapy. A documentation form has been developed to simplify the documentation of the indication.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Zentrum für Rhinologie und Allergologie, Wiesbaden.
- Klinik für Hals-, Nasen- und Ohrenheilkunde, Charité-Universitätsmedizin Berlin, Berlin.
- Klinik für Hals-, Nasen- und Ohrenheilkunde, Universitätsklinikum Münster.
- Klinik für Hals-, Nasen- und Ohrenheilkunde, TUM School of Medicine, Klinikum rechts der Isar, Technische Universität München.
- Zentrum für Allergie und Umwelt (ZAUM), TUM School of Medicine, Klinikum rechts der Isar, Technische Universität München.
- Klinik für Hals-, Nasen- und Ohrenheilkunde, Universitätsmedizin Mainz.
Zitieren
APA
Klimek, L., Bärhold, F., Förster-Ruhrmann, U., Klimek, F., Rott, C., Beule, A. G., Chaker, A., Hagemann, J., Huppertz, T., Hoffmann, T. K., Dazert, S., Deitmer, T., Olze, H., Strieth, S., Wrede, H., Schlenter, W., Welkoborsky, H. J., Wollenberg, B., Albrecht, T., …, & Becker, S. (2026). Anwendung von Omalizumab-Biosimilars bei CRSwNP im deutschen Gesundheitssystem – ein Positionspapier von AeDA und DGHNO-KHC. Laryngo-Rhino-Otologie, 105(04), 210-223. https://doi.org/10.1055/a-2797-4119
Vancouver
Klimek L, Bärhold F, Förster-Ruhrmann U, Klimek F, Rott C, Beule AG, et al. Anwendung von Omalizumab-Biosimilars bei CRSwNP im deutschen Gesundheitssystem – ein Positionspapier von AeDA und DGHNO-KHC. Laryngo-Rhino-Otologie. 2026;105(04):210-223. doi:10.1055/a-2797-4119
BibTeX
@article{Klimek2026,
author = {Klimek, L and Bärhold, F and Förster-Ruhrmann, U and Klimek, F and Rott, C and Beule, A G and Chaker, A and Hagemann, J and Huppertz, T and Hoffmann, T K and Dazert, S and Deitmer, T and Olze, H and Strieth, S and Wrede, H and Schlenter, W and Welkoborsky, H J and Wollenberg, B and Albrecht, T and Rudack, C and Wagenmann, M and Bergmann, Ch and Cuevas, M and Haxel, B and Betz, Ch St and Hoffmann, A S and Beutner, C and Guntinas-Lichius, O and Laudien, M and Gröger, M and Becker, S},
title = {Anwendung von Omalizumab-Biosimilars bei CRSwNP im deutschen Gesundheitssystem – ein Positionspapier von AeDA und DGHNO-KHC},
journal = {Laryngo-Rhino-Otologie},
year = {2026},
volume = {105},
number = {04},
pages = {210--223},
doi = {10.1055/a-2797-4119}
}
EUVIMED